Adenomyoepithelioma (AME) of the male breast is a rare tumor characterized by biphasic proliferation of gland epithelial cells and myoepithelial cells. Though pleomorphic adenoma (PA) is also known to be an epithelial-myoepithelial tumor in the breast, and these tumors are considered to exist on the same spectrum by some authors, to the best of our knowledge, there have been no reports of a clear transition from AME to PA in the male breast. Therefore, the case of an 85-year-old man with AME with PA-like components is presented.
TavassoliFA.Myoepithelial lesions of the breast. Myoepitheliosis, adenomyoepithelioma, and myoepithelial carcinoma. Am J Surg Pathol. 1991;15:554-568.
2.
GaftonBScripcariuVPrutianuI, et al. Challenges in management of male breast adenomyoepithelioma with malignant behavior: case report. Medicine (Baltimore). 2019;98:e17587.
3.
TamuraGMonmaNSuzukiYSatodateRAbeH.Adenomyoepithelioma (myoepithelioma) of the breast in a male. Hum Pathol. 1993;24:678-681.
4.
BernaJDArcasIBallesterABasA.Adenomyoepithelioma of the breast in a male. AJR Am J Roentgenol. 1997;169:917-918.
5.
MoranCASusterSCarterD.Benign mixed tumors (pleomorphic adenomas) of the breast. Am J Surg Pathol. 1990;14:913-921.
6.
RakhaEABadveSEusebiV, et al. Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology. 2016;68:45-56.
7.
BrogiE. Myoepithelial neoplasms. In: RosenP, ed. Rosen’s Breast Pathology 4. Lippincott Williams & Wilkins; 2014 :153-182.
8.
FoschiniMPMorandiLAsioliSGioveGCorradiniAGEusebiV.The morphological spectrum of salivary gland type tumours of the breast. Pathology. 2017;49:215-227.
9.
MollandJGMorganGJWalkerDMLinBP.Pleomorphic adenoma of the parotid and breast in a male patient. Pathology. 2005;37:263-265.
10.
DjakovicAEngelJBGeisingerEHonigATschammlerADietlJ.Pleomorphic adenoma of the breast initially misdiagnosed as metaplastic carcinoma in preoperative stereotactic biopsy: a case report and review of the literature. Eur J Gynaecol Oncol. 2011;32:427-430.
11.
IyengarPCodyHS3rdBrogiE.Pleomorphic adenoma of the breast: case report and review of the literature. Diagn Cytopathol. 2005;33:416-420.
12.
McLarenBKSmithJSchuylerPADupontWDPageDL.Adenomyoepithelioma: clinical, histologic, and immunohistologic evaluation of a series of related lesions. Am J Surg Pathol. 2005;29:1294-1299.
13.
YoonJYChitaleD.Adenomyoepithelioma of the breast: a brief diagnostic review. Arch Pathol Lab Med. 2013;137: 725-729.
14.
GrünewaldIVollbrechtCMeinrathJ, et al. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget. 2015;6:18224-18237.
15.
CiardielloFTortoraG.EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.
16.
UranoMNakaguroMYamamotoY, et al. Diagnostic significance of HRAS mutations in epithelial-myoepithelial carcinomas exhibiting a broad histopathologic spectrum. Am J Surg Pathol. 2019;43:984-994.
17.
El HallaniSUdagerAMBellD, et al. Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases. Am J Surg Pathol. 2018;42:18-27.
18.
GeyerFCLiAPapanastasiouAD, et al. Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nat Commun. 2018;9:1816.
